Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13433609 | 0.87 | MCL1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL3359689 | 0.86 | HCRTR1 (0.35) | PLGPLAUPLATHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL1068215 | 0.86 | PLG (0.36) | PLGPLAUPLATHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL3359708 | 0.86 | PLG (0.36) | PLGPLAUPLATHCRTR1HCRTR2 | |
| SCHEMBL2743957 | 0.85 | HCRTR1 (0.35) | HCRTR1HCRTR2IRAK4AGTR2 | |
| SCHEMBL4615376 | 0.83 | IRAK4 (0.48) | IRAK4 | |
| SCHEMBL4301154 | 0.83 | APAF1 (0.39) | HCRTR1HCRTR2IRAK4 | |
| SCHEMBL25342628 | 0.80 | HCRTR1 (0.46) | HCRTR1HCRTR2AGTR2 | |
| SCHEMBL3502900 | 0.79 | RXFP1 (0.35) | HCRTR1HCRTR2AGTR2NPSR1 | |
| SCHEMBL16418964 | 0.78 | P2RX3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027144-B1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | MSD ITALIA SRL (IT) | 2015-04-29 | — | — | EP | disclosed |
| US-8314062-B2 | Macrocyclic compounds as antiviral agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-11-20 | — | — | US | disclosed |
| US-8178520-B2 | Macrocyclic compounds as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2012-05-15 | — | — | US | disclosed |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-12-17 | — | — | US | disclosed |
| US-20090258891-A1 | Macrocyclic Compounds As Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | PLG 4289/4885PLAU 3555/4885PLAT 3263/4885 |
| US-20090258891-A1 | Macrocyclic Compounds As Antiviral Agents | ZC3HAV1, HAVCR2, ZC3HAV1L | PLG 4486/4885PLAU 3986/4885PLAT 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.